Comparative Pharmacology
Head-to-head clinical analysis: CLARAVIS versus SOTRET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARAVIS versus SOTRET.
CLARAVIS vs SOTRET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isotretinoin, a retinoid, reduces sebum production, inhibits sebaceous gland activity, and normalizes follicular keratinization. It also exhibits anti-inflammatory effects.
Binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription to reduce sebum production, normalize follicular keratinization, and inhibit Propionibacterium acnes growth.
Oral: 30 mg once daily after a meal for 12 weeks; administration with high-fat meal increases absorption.
Oral isotretinoin 0.5-1 mg/kg/day divided twice daily for 15-20 weeks.
None Documented
None Documented
Terminal half-life: 19-24 hours in adults; prolonged in renal impairment (up to 50 hours in ESRD).
Clinical Note
moderateIsotretinoin + Estrone sulfate
"The therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Estramustine
"The therapeutic efficacy of Estramustine can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Dienogest
"The therapeutic efficacy of Dienogest can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Medroxyprogesterone acetate
Terminal elimination half-life: 18-20 hours in adults; steady-state achieved after 5-7 days of dosing.
Renal: 90% as unchanged drug; fecal: 5%; biliary: <1%.
Primarily hepatic metabolism with renal excretion of metabolites (approximately 60-80% in urine) and fecal elimination (15-30%).
Category C
Category C
Retinoid
Retinoid
"The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Isotretinoin."